FDAnews Announces Publication Dedicated to Genomics Industry
Online Publication Covers Emerging Trends,
Opportunities and Developments on the Forefront in Fast-Changing Field
FALLS CHURCH, Va., July 1 /PRNewswire/ -- FDAnews today announced its newest publication, Genomics Newswire, the first independent publication dedicated to in-depth, original reporting and analysis on the genomics industry. "The deals that are being made now will lay the groundwork for the entire future of the genomics field," says Cynthia A. Carter, president of FDAnews, "and they're happening incredibly quickly. It's an all-out race to get products to market and recoup the R&D investment." Published weekly online, Genomics Newswire provides up-to-the-minute, global coverage that executives at pharmaceutical firms, biotech companies, genomics companies, diagnostics manufacturers, bioinformatic companies, computer firms, law firms and investment firms need to take advantage of opportunities in the genomics industry, stay current on rapidly-evolving legislation and other developments and make business decisions quickly. Genomics Newswire covers current and emerging issues -- including new therapies in clinical trials, diagnostics, therapeutic cloning and stem cell research, agricultural biotechnology, nutraceutical developments, pharmacogenomics, drug discovery, target identification and validation and more. Each issue goes beyond the wire services and press-release driven stories to bring the subscriber well researched, multiple-source news articles that provide valuable insight on: developments in drug discovery, evolving legal and regulatory decisions, bringing a product to market, investment opportunities, research collaboratives, industry changes and more. For a limited time, FDAnews is offering charter subscriptions to Genomics Newswire at $200 off the regular $795 subscription rate. For subscription information, contact Bailey Sterrett at 703-538-7600 or email@example.com . Genomics Newswire is published by FDAnews, publishers of Washington Drug Letter, Part 11 Compliance Report, Generic Line, Devices & Diagnostics Letter, Regulatory Watchdog Service, and many other information services to help pharmaceutical, biotech and medical device executives meet regulatory and business challenges. MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X76828933
More by this Source
FDAnews Announces Clinical Trials Disclosure and Transparency Summit
Jun 13, 2013, 10:17 ET
Dietary Supplement GMP Inspectional Readiness Virtual Conference
Jun 11, 2013, 06:04 ET
FDAnews Announces Social Media Strategies for Drug & Device Companies Virtual Conference
May 14, 2013, 13:41 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.